Across TCGA pan-cancer cohorts, ETV2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ETV2 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ETV2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ETV2 expression acts as an unfavorable survival marker.
BLCA, LUAD, and LUSC are the cancer types where ETV2 Mutation most reproducibly stratifies survival.